Vanda Pharmaceuticals Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+1.25%
vs ±11.7% implied · ×0.11
shaded = implied · ▲▼ = realized
Vanda Pharmaceuticals has 13 disclosed suppliers and 0 disclosed customers in SEC filings.
We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.
SentenceIn February 2004, we entered into a license agreement with Bristol-Myers Squibb (BMS) under which we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ ® .
SentenceIn April 2012, we entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize NEREUS TM for all human indications.
SentenceIn December 2023, we purchased the rights to market and sell PONVORY ® in the U.S. and Canadian markets from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company.
VNDA 10-Kaccession 0001628280-26-007460
SentenceThe FDA has approved Abbreviated New Drug Applications (ANDA) for generic versions of HETLIOZ ® for Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. (Apotex) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN).
VNDA 10-Kaccession 0001628280-26-007460
SentenceThe FDA has approved Abbreviated New Drug Applications (ANDA) for generic versions of HETLIOZ ® for Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. (Apotex) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN).
VNDA 10-Kaccession 0001628280-26-007460
SentenceAt that time, we had certain worldwide exclusive rights relating to Fanapt ® , which we obtained pursuant to a sublicense agreement entered into with Novartis Pharma AG (Novartis) in June 2004.
VNDA 10-Kaccession 0001628280-26-007460
SentenceIn 2022, we announced a research and development collaboration agreement with OliPass Corporation (OliPass) to jointly develop a set of ASO molecules based on OliPass' proprietary modified peptide nucleic acids.
VNDA 10-Kaccession 0001628280-26-007460
SentenceWe have agreements in place with Patheon Pharmaceuticals Inc. and Patheon Inc. (collectively, Patheon), subsidiaries of Thermo Fisher Scientific, for the manufacture of Fanapt ® and HETLIOZ ® .
VNDA 10-Kaccession 0001628280-26-007460
SentenceIn March 2017, we entered into a license agreement with the University of California San Francisco (UCSF), under which we acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors.
VNDA 10-Kaccession 0001628280-26-007460
Linked news
Vanda Pharmaceuticals Inc.
3.79
—
Expected move
No implied move.